Oppenheimer Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective boosted by research analysts at Oppenheimer from $48.00 to $52.00 in a research note issued on Monday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 87.86% from the company’s current price.

Several other research firms also recently commented on DNTH. Raymond James boosted their target price on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Wedbush lowered their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Thursday, September 26th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $27.68 on Monday. Dianthus Therapeutics has a 52-week low of $6.58 and a 52-week high of $33.77. The business’s 50 day simple moving average is $27.73 and its two-hundred day simple moving average is $26.64. The firm has a market cap of $812.96 million, a P/E ratio of -11.07 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 22.37% and a negative net margin of 1,250.32%. On average, equities analysts forecast that Dianthus Therapeutics will post -2.28 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently added to or reduced their stakes in DNTH. Bain Capital Life Sciences Investors LLC purchased a new position in Dianthus Therapeutics in the first quarter valued at about $89,761,000. RA Capital Management L.P. purchased a new position in Dianthus Therapeutics in the first quarter valued at approximately $69,990,000. Great Point Partners LLC grew its holdings in Dianthus Therapeutics by 21.3% during the second quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after purchasing an additional 132,929 shares during the period. Vanguard Group Inc. increased its position in Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after buying an additional 384,182 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in shares of Dianthus Therapeutics in the first quarter valued at $11,251,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.